Cullinan Therapeutics, Inc. (CGEM) SEC Filings & Earnings Calls

Regulatory approval not guaranteed; PDUFA date for monotherapy is Feb 27, 2027.

“NDA for monotherapy under review with PDUFA target action date of February 27, 2027.”

No actual clinical data released; forward-looking statements about planned milestones carry execution risk.

“The press release outlines anticipated milestones but does not provide any clinical results.”

Higher grade ≥3 AEs in combination arm (87.1% vs 54.4%), primarily hematologic; manageable but notable.

“Grade ≥3 AEs occurred more frequently for zipalertinib plus chemotherapy than for chemotherapy alone (87.1% vs. 54.4%), but these were primarily manageable hematologic AEs (58.6% vs. 28.7%).” · word for word

Regulatory approval not yet granted; FDA discussions pending.

“Pending discussions with the U.S. Food and Drug Administration, Taiho and the Company plan to pursue U.S. regulatory approval.” · word for word

Clinical trial failure risk

“We have a history of significant operating losses and have had negative cash flows from operations since our inception and expect to continue to generate operating losses for the foreseeable future.” · word for word

Dependence on regulatory approval

“The U.S. FDA assigned a Prescription Drug User Fee Act target action date of February 27, 2027.” · word for word

Financing risk

“We may also require additional capital to pursue in-licenses or acquisitions of other programs to further expand our pipeline.” · word for word

Competition risk

“We are developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer.”

Clinical-stage company with no approved products; pipeline risk.

“Clinical-stage biopharmaceutical company; no revenue from product sales.”

Interim data; final results may differ; clinical trial risks remain.

“The clinical trials referenced ... are ongoing, and the data described are interim, subject to change”

Early-stage clinical data; results may change with additional patients and follow-up.

“The clinical trials referenced in this Current Report on Form 8-K are ongoing, and the data described are interim, subject to change, and based on data available as of a specified date.” · word for word

Pre-revenue, history of losses, needs additional capital

“We have a history of significant operating losses and have had negative cash flows from operations since our inception and expect to continue to generate operating losses for the foreseeable future.” · word for word

Clinical and regulatory risk for pipeline

“There can be no assurance that our research and development will be successfully completed, that adequate protection for our intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable.” · word for word

Clinical-stage company with no approved products; reliance on pipeline success.

“Clinical-stage biopharmaceutical company; net loss $49.7M; no revenue.”

Regulatory and clinical trial risk for multiple candidates.

“Initial data expected mid-2026; PDUFA date Feb 2027; trial enrollment ongoing.”

Pre-commercial stage; no revenue

“Because we are not a commercial-stage company, we did not have any revenue during the periods presented.” · word for word

Net loss widening

“Our net loss in 2025 increased $52.3 million, or 31.2%, from 2024.” · word for word

Program discontinuation risk

“In November 2025, we discontinued the development of our Cullinan Amber and Cullinan MICA programs.” · word for word

Clinical trial failure risk

“In May 2025, following a review of the CLN-619 data from the disease-specific expansion cohorts for endometrial and cervical cancers, we announced discontinuation of further development of CLN-619 in patients with gynecological cancers as preliminary results did not meet our internal threshold for advancement.” · word for word

Dependence on Taiho for zipalertinib

“We are co-developing zipalertinib, for which Taiho holds the intellectual property rights, with an affiliate of Taiho.” · word for word

No approved products or revenue

“We do not have any products approved for sale and have not generated any revenue from product sales.” · word for word

Clinical-stage company with no approved products or revenue; net loss widening as R&D spending increases.

“Net loss attributable to Cullinan was $219.9 million for the full year 2025, compared to $167.4 million for the full year 2024.”

Dependence on clinical trial success for CLN-978, CLN-049, and zipalertinib; regulatory approval not guaranteed.

“Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026” · word for word

Clinical-stage biotech with no approved products; pipeline risk

“All programs in clinical development; no approved products; data readouts in 2026”

Preliminary cash balance subject to change

“Preliminary unaudited; subject to completion of financial close”

Phase 1 data is early-stage; dose escalation ongoing, expansion cohorts planned in early 2026; safety profile favorable but limited sample size.

“Dose escalation continues in this ongoing Phase 1 study, with expansion cohorts planned in early 2026.” · word for word

Pipeline setback; loss of potential future revenue from CLN-617.

“Termination of license for CLN-617, a cancer immunotherapy product.”

Clinical-stage company with no approved products; reliance on successful clinical trials and regulatory approval.

“No revenue; net loss; cash runway into 2029.”

Discontinuation of CLN-619 and CLN-617 programs may indicate pipeline risk.

“CLN-619 and CLN-617 programs discontinued after review of emerging clinical data.” · word for word

Clinical trial failure risk

“In November 2025, after a review of the emerging clinical data in patients with NSCLC and multiple myeloma, we decided not to pursue further development of CLN-619.” · word for word

Regulatory delay risk

“If the government shutdown continues, acceptance and review of the NDA submission for zipalertinib may be delayed.” · word for word

Funding risk

“Our future viability is dependent on the success of our research and development and our ability to access additional capital to fund our operations.” · word for word

Clinical trial risk: early-stage data, small sample size, ongoing dose escalation.

“Dose escalation continues in this ongoing Phase 1 study.” · word for word

Safety profile manageable but includes CRS (40%) and febrile neutropenia (17.5%).

“The most common TEAEs included CRS (40%), infusion-related reaction (35%), and febrile neutropenia (17.5% each).”